Venous thromboembolism is a risk with several contemporary HRT formulations, consistent with earlier data. Several ...

Patients lost an average of 20.2% of their weight with tirzepatide over 72 weeks versus 13.7% with semaglutide.

Lack of transparency in early studies and manufacturer summaries are among the issues uncovered during litigation.

An echo analysis highlights changes in the right ventricle that contribute to patient’s improved QoL with tricuspid TEER.

News from the American Heart Association 2024 Scientific Sessions took seven of the 10 top slots this month.

Though X (formerly Twitter) was once a place many cardiologists found community and opportunity, many are jumping ship.

In the CONDUCT-TAVI study, the use of a self-expanding valve was not associated with an increased risk of pacemaker.

Much remains to learn about this anatomical finding, seen in about one-third of adults, and how it may affect stroke risk.

An increased risk of cardiovascular disease may be present as early as 30 years before a type 2 diabetes diagnosis is made, ...

Written to offer advice where formal guidelines fall short, the document urges a balance between bleeding and ischemic risk.

The SMART trial raised questions about balloon-expandable valves in small aortic annuli; these new data offer some answers.

Acoramidis becomes the second drug ever approved for this condition, based on the results of the ATTRibute-CM trial.